Levo-T

Product manufactured by Neolpharma, Inc.

Application Nr Approved Date Route Status External Links
NDA021342 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Levo-T Is L-Thyroxine (T 4 ) Indicated For: Hypothyroidism: As Replacement Therapy In Primary (Thyroidal), Secondary (Pituitary), And Tertiary (Hypothalamic) Congenital Or Acquired Hypothyroidism. ( 1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, Tsh) Suppression: As An Adjunct To Surgery And Radioiodine Therapy In The Management Of Thyrotropin-Dependent Well-Differentiated Thyroid Cancer. ( 1 ) Limitations Of Use: - Not Indicated For Suppression Of Benign Thyroid Nodules And Nontoxic Diffuse Goiter In Iodine-Sufficient Patients. - Not Indicated For Treatment Of Hypothyroidism During The Recovery Phase Of Subacute Thyroiditis. Hypothyroidism Levo-T Is Indicated As A Replacement Therapy In Primary (Thyroidal), Secondary (Pituitary), And Tertiary (Hypothalamic) Congenital Or Acquired Hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, Tsh) Suppression Levo-T Is Indicated As An Adjunct To Surgery And Radioiodine Therapy In The Management Of Thyrotropin-Dependent Well-Differentiated Thyroid Cancer. Limitations Of Use: Levo-T Is Not Indicated For Suppression Of Benign Thyroid Nodules And Nontoxic Diffuse Goiter In Iodine-Sufficient Patients As There Are No Clinical Benefits And Overtreatment With Levo-T May Induce Hyperthyroidism [See Warnings And Precautions (5.4) ]. Levo-T Is Not Indicated For Treatment Of Hypothyroidism During The Recovery Phase Of Subacute Thyroiditis.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Levothyroxine Sodium LEVOTHYROXINE SODIUM ZINC3830993

Comments